This company listing is no longer active
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Olink Holding Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Olink Holding has been growing earnings at an average annual rate of 8%, while the Life Sciences industry saw earnings growing at 16.8% annually. Revenues have been growing at an average rate of 31.7% per year.
Anahtar bilgiler
8.0%
Kazanç büyüme oranı
85.3%
EPS büyüme oranı
| Life Sciences Sektör Büyümesi | 21.5% |
| Gelir büyüme oranı | 31.7% |
| Özkaynak getirisi | -7.3% |
| Net Marj | -19.7% |
| Son Kazanç Güncellemesi | 31 Mar 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Revenues Tell The Story For Olink Holding AB (publ) (NASDAQ:OLK)
Jun 21
Olink Holding AB (publ) (NASDAQ:OLK) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 28Is It Time To Consider Buying Olink Holding AB (publ) (NASDAQ:OLK)?
Oct 19We're Interested To See How Olink Holding (NASDAQ:OLK) Uses Its Cash Hoard To Grow
Jul 04A Look At The Intrinsic Value Of Olink Holding AB (publ) (NASDAQ:OLK)
Jun 13At US$21.02, Is It Time To Put Olink Holding AB (publ) (NASDAQ:OLK) On Your Watch List?
May 23Olink Holding (NASDAQ:OLK) Is In A Strong Position To Grow Its Business
Mar 20Calculating The Intrinsic Value Of Olink Holding AB (publ) (NASDAQ:OLK)
Dec 31Olink Holding partners with Discovery Life Sciences to establish commercial platform
Sep 20We're Hopeful That Olink Holding (NASDAQ:OLK) Will Use Its Cash Wisely
Sep 16Olink GAAP EPS of -$0.04, revenue of $27.5M; reaffirms FY22 guidance
Aug 11We're Not Very Worried About Olink Holding's (NASDAQ:OLK) Cash Burn Rate
May 16Olink Holding Plans Strong 2022 Spending Amid Growth Slowdown
May 13Olink Holding AB (publ) (NASDAQ:OLK) Just Reported, And Analysts Assigned A US$29.75 Price Target
Feb 17Companies Like Olink Holding (NASDAQ:OLK) Can Afford To Invest In Growth
Jun 25Gelir ve Gider Dağılımı
Olink Holding nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 24 | 171 | -34 | 135 | 38 |
| 31 Dec 23 | 170 | -32 | 130 | 34 |
| 30 Sep 23 | 159 | -19 | 114 | 29 |
| 30 Jun 23 | 147 | -18 | 107 | 27 |
| 31 Mar 23 | 145 | -15 | 103 | 27 |
| 31 Dec 22 | 140 | -13 | 99 | 26 |
| 30 Sep 22 | 126 | -30 | 95 | 28 |
| 30 Jun 22 | 114 | -35 | 92 | 26 |
| 31 Mar 22 | 104 | -36 | 87 | 24 |
| 31 Dec 21 | 95 | -43 | 81 | 22 |
| 30 Sep 21 | 78 | -27 | 70 | 16 |
| 30 Jun 21 | 70 | -26 | 57 | 13 |
| 31 Mar 21 | 60 | -28 | 44 | 11 |
| 31 Dec 20 | 54 | -24 | 33 | 10 |
| 31 Dec 19 | 46 | -37 | 45 | 7 |
Kaliteli Kazançlar: OLK şu anda kârlı değil.
Büyüyen Kar Marjı: OLK is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: OLK is unprofitable, but has reduced losses over the past 5 years at a rate of 8% per year.
Büyüme Hızlandırma: Unable to compare OLK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: OLK is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.5%).
Özkaynak Getirisi
Yüksek ROE: OLK has a negative Return on Equity (-7.3%), as it is currently unprofitable.